Articles

IFCT-1001 CHIVA trial: A phase II study of carboplatin (Ca) plus pemetrexed (P) followed by P maintenance, as first-line therapy for human immunodeficiency virus (HIV)-associated advanced non-squamous non-small-cell lung cancer (NS-NSCLC)

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Local consolidative therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST): Results of a multi-institutional phase II randomized study

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate-017/057 2-y update and exploratory cytokine profile analyses

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Open-label, multicenter, randomized phase III trial of pemetrexed/carboplatin doublet vs pemetrexed singlet in chemotherapy-naïve elderly patients aged 70 or more with advanced non-squamous non–small-cell lung cancer and good performance status

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Pooled analysis of venous thromboembolism (VTE) from four trials of necitumumab and chemotherapy for stage IV non-small cell lung cancer (NSCLC)

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–positive NSCLC

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Response to tyrosine kinase inhibitors in advanced non–small-cell lung cancer with concomitant c-MET overexpression and EGFR mutation

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer

ASCO 2016 – Lung Cancer, ASCO

Conference Correspondent

Understanding the Subsets of Lymphoma and Treating for Them

Understanding the Subsets of Lymphoma and Treating for Them

By Joseph Connors, MD

Joseph Connors, MD, explains how the understanding of the disease has evolved leading to the categorization of subsets and consequently resulted in the development of newer therapies to address these subsets.

Page 164 of 329